Sign in
CompletedNo phase

Steadysense -Early Detection of Postoperative Infections Through Continuous Temperature Measurement

Key facts

Who runs it
Medical University of Graz
Where
Austria1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
103 people enrolled
Started
14 Aug 2023
Ended
15 Jul 2024
Type of study
Observational
Treatments tested
  • Steadytemp®
Record updated
30 July 2024

Who can take part

Age
18 years and older
Sex
Women and men

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • participant is willing and able to give informed consent for participation in the study
  • age 18 years and above
  • visceral surgery procedure within the last two days
  • inpatient stay on the ICIÜ (Interdisciplinary surgical intensive care unit) or normal ward

Who cannot take part

  • allergy to the ingredients of skin patches
  • major psychiatric diseases including history of drug or alcohol abuse
  • chronic inflammatory disease in the medical history
  • predicted inpatient stay is less than 5 days
  • operational wound is too close to the patch adhesive site
  • the skin at the intended adhesive site of the patch is not intact
  • BMI > 33

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this observational study is to review whether postoperative infections can be detected earlier by a continuous measurement of body temperature of patients compared to single daily measurements. Within 25 weeks 100 patients, which underwent visceral surgery less than 48h ago, will be included. A patch (Steadytemp ®) will be attached to participants, continuously measuring the body temperature. In addition infection parameters and medication of the participants will be documented.

Treatments tested

  • Steadytemp®

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
30 July 2024